Joseph Haas

6 days ago | insights.citeline.com | Jessica Merrill |Joseph Haas

Q1 S&E In Brief: Tracking New Launches And Catalysts In BiopharmaNeurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

6 days ago | insights.citeline.com | Mandy Jackson |Kevin Grogan |Joseph Haas |Andrew McConaghie

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings. HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

1 week ago | insights.citeline.com | Joseph Haas

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This YearSeven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings. Viatris hopes to get FDA approval for a meloxicam formulation in acute pain (Shutterstock)

1 week ago | insights.citeline.com | Joseph Haas

Marea Eyes Cardioprotective Benefit With ANGPTL4 InhibitionPhase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes. Marea hopes ANGPTL4 inhibition can benefit high-risk cardiovascular patients • Source: Shutterstock

1 week ago | insights.citeline.com | Joseph Haas

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom DataThe biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action. Aldeyra plans to take its dry eye candidate to the FDA for a third shot at approval • Source: Alamy